Printer Friendly

Browse Ipilimumab topic

Articles

1-216 out of 216 article(s)
Title Author Type Date Words
Checkmate presents new clinical trial translational data with Vidutolimod. Apr 11, 2021 190
Achilles presents patient case study from ongoing Phase I/IIa THETIS trial. Apr 11, 2021 203
Bristol Myers Squibb's Opdivo plus Chemotherapy and Opdivo plus Yervoy Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma. Apr 8, 2021 520
Provectus receives notice of allowance for patent for PV-10 immunotherapy. Mar 30, 2021 212
NA Proactive news snapshot: ElectraMeccanica, Marrone Bio, Predictmedix, VolitionRx, CleanSpark, HempFusion UPDATE ... Mar 24, 2021 3952
Idera Pharmaceuticals announces ILLUMINATE-301 trial misses primary endpoint. Mar 18, 2021 238
PharmaDrug welcomes top Memorial Sloan Kettering gastrointestinal oncologist Yelena Janjigian to its scientific and clinical advisory board. Mar 5, 2021 398
Resected stage IV melanoma: Strong results with adjuvant immunotherapy. Jancin, Bruce Clinical report Feb 1, 2021 394
Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease. Irshaid, Lina; Robert, Marie E.; Zhang, Xuchen Report Feb 1, 2021 6049
US FDA Accepts for Priority Review Application for Opdivo Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma. Jan 20, 2021 484
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma. Jan 5, 2021 692
Exploratory, Participatory and Iterative Assessment of Value: A Response to Recent Commentaries. Grutters, Janneke P.C.; Govers, Tim M.; Nijboer, Jorte; Tummers, Marcia; van der Wilt, Gert Jan; Rov Jan 1, 2021 2720
Vaccine regimen boosts immune responses in melanoma study. Rans, Caleb Clinical report Jan 1, 2021 429
Non-Small Cell Lung Cancer: Part II. Lacovara, Jane; Bohnenkamp, Susan Column Jan 1, 2021 1966
Immunotherapy Offers Hope to Men with Advanced Prostate Cancer: Treatment reactivates immune system protections. Jan 1, 2021 540
Immune Therapies and Advanced Cancer. Armstrong, Andrew J. Jan 1, 2021 242
TRACON Pharmaceuticals says first patient dosed in ENVASARC registration trial to treat soft-tissue sarcoma cancer. Dec 11, 2020 377
Real-world survival data with checkpoint inhibitors: Studies show outcomes may differ from clinical trial results. Fuerst, Mark L. Clinical report Dec 1, 2020 1176
European Commission Approves Opdivo plus Yervoy with Two Cycles of Chemotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. Nov 9, 2020 424
TRACON Pharmaceuticals driving the development of targeted therapies for cancer. Nov 5, 2020 990
Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. Swami, Umang; Chennamadhavuni, Adithya; Borcherding, Nicholas; Bossler, Aaron D.; Mott, Sarah L.; Ga Nov 1, 2020 4591
Melanoma treatment may offer hope after immunotherapy. Davenport, Liam Nov 1, 2020 729
US FDA approves Opdivo in combination with Yervoy. Oct 5, 2020 201
10,000 patients waiting 15 months for medicines; Political bid to cut funding to blame for huge backlog. TREVOR QUINN Oct 5, 2020 329
US FDA approves Opdivo in combination with Yervoy. Oct 5, 2020 197
Bristol-Myers says FDA approves Opdivo with Yervoy for mesothelioma treatment. Oct 2, 2020 214
FIRST PATIENTS DOSED WITH INT230-6 AND KEYTRUDA. Clinical report Oct 1, 2020 832
Real-world data support adjuvant immunotherapy for stage III melanoma. Otto, M. Alexander Oct 1, 2020 531
Xilio Therapeutics Names Humphrey to Board of Directors. Sep 30, 2020 346
Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb's Yervoy in a Phase 2 Study. Clinical report Sep 18, 2020 545
Idera Pharmaceuticals to present tilsotolimod data at ESMO Virtual Congress. Sep 15, 2020 367
In-silico Analysis to Determine the Efficient Drug for Malignant Melanoma using Molecular Dynamics. Pallavi, M.S.; Kumar, H.S. Pramod Report Sep 1, 2020 2391
Mathematical Modelling of the Inhibitory Role of Regulatory T Cells in Tumor Immune Response. Yang, Zhongtao; Yang, Cuihong; Dong, Yueping; Takeuchi, Yasuhiro Aug 31, 2020 11877
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Rogiers, Anne; Leys, Christophe; Lauwyck, Justine; Schembri, Adrian; Awada, Gil; Schwarze, Julia Kat Aug 31, 2020 7686
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. Xiao, Yan; Zeng, Lin; Shen, Qinglin; Zhou, Zhiyong; Mao, Zhifang; Wang, Qin; Zhang, Xiquan; Li, Ying Aug 31, 2020 6356
Shorts. Klotter, Jule Aug 1, 2020 1918
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma. Jeyakumar, Nikeshan; Etchegaray, Mikel; Henry, Jason; Lelenwa, Laura; Zhao, Bihong; Segura, Ana; Buj Jul 31, 2020 2738
Hypocalcemia with Immune Checkpoint Inhibitors: The Disparity among Various Reports. Nalluru, Swarna Sri; Piranavan, Paramarajan; Ning, Ying; Ackula, Haritha; Siddiqui, Ahmad D.; Trived Jun 30, 2020 3014
CytomX announces preclinical data from Anti-CTLA-4 probody therapeutic programs. Jun 22, 2020 202
Jounce Therapeutics presents preclinical data on JTX-1811. Jun 22, 2020 374
The Cancer Immunotherapy Biomarker Testing Landscape. Walk, Eric E.; Yohe, Sophia L.; Beckman, Amy; Schade, Andrew; Zutter, Mary M.; Pfeifer, John; Berry, Jun 1, 2020 16518
An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient. Krukowska, Kinga; Kieszko, Robert; Kurek, Katarzyna; Chmielewska, Izabela; Krawczyk, Pawel; Milanows May 31, 2020 2517
Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma. Singh, Navdeep; Singh Lubana, Sandeep; Constantinou, George; Leaf, Andrea N. May 31, 2020 3548
Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. Ahmad Hasan Albitar, Hasan; Duma, Narjust; Leventakos, Konstantinos; De Moraes, Alice Gallo May 31, 2020 3226
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. Nie, Run-Cong; Zhao, Chong-Bang; Xia, Xiao-Wei; Luo, Ying-Shan; Wu, Ting; Zhou, Zhi-Wei; Yuan, Shu-Q Report May 31, 2020 6865
CytomX Therapeutics programs 'highlighted at ASCO20 virtual program. May 29, 2020 237
Tracon highlights updated Envafolimab results in MSI-H/dMMR colorectal cancer. Clinical report May 29, 2020 225
AGREEMENT EXPANDS GENPREX ONCOLOGY FRANCHISE. May 27, 2020 579
FDA approves Bristol-Myers' Opdivo+Yervoy w/ limitd chemo in 1L NSCLC. May 26, 2020 206
US Food and Drug Administration Approves Opdivo + Yervoy as First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1a[per mille][yen sign]1%. May 18, 2020 804
Oncimmune's study data to be featured at prestigious cancer research conference. Conference news May 15, 2020 334
Immupharma lifted by US university study. Clinical report May 15, 2020 3351
Proactive news headlines: ImmuPharma, Tiziana Life Sciences, Echo Energy, Bango ... May 15, 2020 3297
TRACON Pharmaceuticals announces successful Type B meeting with FDA for Pivotal Study of Envafolimab in sarcoma. May 12, 2020 363
Genprex shares soar as it strikes new worldwide license deal with MD Anderson for Oncoprex. May 6, 2020 493
NCCN panel: Defer nonurgent skin cancer care. Otto, M. Alexander May 1, 2020 613
Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab. Cuenca, John A.; Laserna, Andres; Reyes, Maria P.; Nates, Joseph L.; Botz, Gregory H. Apr 30, 2020 2059
Idera Pharmaceuticals announces final safety data from ILLUMINATE-204 trial. Apr 21, 2020 440
Bristol Myers Squibb Touts Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo, Yervoy Combination vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma. Apr 20, 2020 284
Membranoproliferative Glomerulonephritis Associated with Nivolumab Therapy. Cruz-Whitley, Jessica; Giehl, Nolan; Jen, Kuang-Yu; Young, Brian Mar 31, 2020 2208
TRACON Pharmaceuticals requests FDA meeting to discuss pivotal study design for Envafolimab to treat sarcoma. Mar 17, 2020 450
NA Proactive news snapshot: Ideanomics, Lexaria Bioscience, Seelos Therapeutics, Helix BioPharma UPDATE ... Mar 17, 2020 2495
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. Khan, Alisha; Riaz, Sana; Carhart, Robert, Jr. Mar 1, 2020 1999
Isolated testicular vasculitis due to immune checkpoint inhibitor. Weiner, Rebecca; Hanson, Britt; Rehman, Jamaal; Sun, Bob Mar 1, 2020 1308
Opdivo Plus Yervoy Demonstrates Continued Survival Benefit at 42-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma. Feb 19, 2020 647
Cancer deaths on decline. Feb 17, 2020 741
Higher Dose Combo to Treat Bladder Cancer. Feb 1, 2020 213
US FDA accepts Bristol-Myers Squibb's supplemental Biologics License Application for Opdivo in combination with Yervoy. Jan 17, 2020 226
US FDA accepts Bristol-Myers Squibb's supplemental Biologics License Application for Opdivo in combination with Yervoy. Jan 17, 2020 222
Cancer Mortality Continues Steady Decline. Jan 11, 2020 1122
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Cembrola, Biancamaria; Ruzza, Valentino; Troise, Fulvia; Esposito, Maria Luisa; Sasso, Emanuele; Caf Jan 1, 2020 15860
A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer. Ashinuma, Hironori; Mizuno, Satoko; Yoshida, Yasushi; Shingyoji, Masato Jan 1, 2020 2228
Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation. Anson, David; Norton, Joseph; Chaucer, Benjamin; Bansal, Saurabh Jan 1, 2020 1273
Preventive CTLA-4-Ig Treatment Reduces Hepatic Egg Load and Hepatic Fibrosis in Schistosoma mansoni-Infected Mice. Sombetzki, Martina; Rabes, Anne; Bischofsberger, Miriam; Winkelmann, Franziska; Koslowski, Nicole; S Dec 31, 2019 6338
Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. Zhang, Xueyan; Chen, Li; Zhao, Yawei; Yin, Huiru; Ma, He; He, Miao Dec 31, 2019 9556
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. Imoto, Koji; Kohjima, Motoyuki; Hioki, Tomonobu; Kurashige, Tomoyuki; Kurokawa, Miho; Tashiro, Shige Dec 31, 2019 7227
An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Baseri, Babak; Samra, Bachar; Tam, Eric; Chiu, Edwin; Leaf, Andrea Dec 31, 2019 4860
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barre Syndrome: A Case Report and Review of the Literature. Gravbrot, Nicholas; Scherer, Katalin; Sundararajan, Srinath Dec 31, 2019 3220
Omeros' Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors. Dec 19, 2019 408
Immunotherapy Drugs Market Share Analysis, Future Growth Insights, Trends Analysis, Dynamics and Industry Overview By 2023. Industry overview Dec 13, 2019 1012
Immunotherapy Drugs Market Size Is Projected to Grow at a CAGR of 8.9% By 2023. Dec 12, 2019 1054
Global Therapeutic Proteins Market Report 2020: Market was Valued at $93.14 Billion in 2018 and is Expected to Grow to $172.87 Billion through 2022. Report Dec 10, 2019 653
What the Oncologist Needs From the Pathologist for Immune Therapies. Bernicker, Eric H. Dec 1, 2019 3001
Corrigendum to "Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience". Karivedu, Vidhya; Eldessouki, Ihab; Correa, Zelia; Taftaf, Ahmad; Zhu, Zheng; Makramalla, Abouelmagd Correction notice Nov 30, 2019 235
Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab. Lima, Gian; Kahn, Adriana; Sama, Shashank; Savage, Jacqueline Nov 30, 2019 1126
Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy. Alrifai, Taha; Ali, Faisal Shaukat; Saleem, Sameer; Ruiz, Diana Carolina Miranda; Rifai, Dana; Youna Nov 30, 2019 1964
Bristol-Myers Squibb Provides Update on CheckMate -915 for Opdivo Plus Yervoy Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1%. Clinical report Nov 21, 2019 124
Skin cancer 'milestone' 60 SECONDS ON. DR MIRIAM STOPPARD Nov 15, 2019 169
Skin cancer 'milestone'. DR MIRIAM STOPPARD Nov 15, 2019 169
US FDA Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo Plus Yervoy Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma. Nov 13, 2019 622
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) - Regeneron Provides Updates on Phase 3 Libtayo[R] (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer -- 5/11/2019. Nov 13, 2019 1613
Bristol-Myers Squibb UK (NYSE:BMY) - U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular Carcinoma -- 11/11/2019. Nov 12, 2019 265
Bristol Myers Squibb UK. Nov 12, 2019 1882
Bristol-Myers Squibb (NYSE:BMY). Nov 11, 2019 1889
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) - Regeneron Provides Updates on Phase 3 Libtayo[R] (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer -- 5/11/2019. Nov 6, 2019 1611
Bristol Myers Squibb UK. Nov 6, 2019 1888
Regeneron provides update on Phase 3 Libtayo development program. Nov 5, 2019 293
Jounce Therapeutics to present safety, efficacy data on JTX-4014. Nov 5, 2019 305
Getting the Best out of Academic-Industrial Collaborations. Gwynne, Peter Nov 1, 2019 1363
Nivolumab-ipilimumab nets long-term survival in advanced melanoma. London, Susan Nov 1, 2019 560
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma. Zhao, Lingdi; Yang, Yonghao; Ma, Baozhen; Li, Wei; Li, Tiepeng; Han, Lu; Zhang, Yong; Shang, Yi-Man; Clinical report Oct 31, 2019 6049
Mustang Bio announces City of Hope receives $4.1M in grant awards. Oct 10, 2019 209
Calithera Biosciences completes patient enrollment in CANTATA trial. Oct 3, 2019 202
Bristol-Myers Squibb Shows Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Oct 1, 2019 149
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Duffy, Michael J.; Crown, John Oct 1, 2019 8376
Five-Year Outcomes for Opdivo in Combination with Yervoy Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma. Oct 1, 2019 654
Adjuvant Treatment with Opdivo Continues to Demonstrate Extended Recurrence-Free Survival at Three Years in Resected High-Risk Melanoma Patients, According to BMY. Oct 1, 2019 132
Idera Pharmaceuticals announces initiation of ILLUMINATE-206 trial. Sep 30, 2019 221
Nivolumab Therapy Prolongs Survival in Advanced Melanoma; Overall survival at five years longer with nivolumab + ipilimumab, nivolumab alone versus ipilimumab. Sep 30, 2019 290
Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome. Keating, Matthew; Giscombe, Lisa; Tannous, Toufic; Hartshorn, Kevan Sep 30, 2019 2638
Hopes for skin cancer victims. Sep 29, 2019 186
Immunotherapy drugs when combined prevent melanoma progression. ANI Sep 29, 2019 465
CStone Pharmaceuticals reveals preliminary results from Phase Ia trial of anti-CTLA-4 antibody. Sep 23, 2019 293
CStone Pharmaceuticals reveals preliminary results from Phase Ia trial of anti-CTLA-4 antibody. Sep 23, 2019 289
Ascites Market Size, 2019 Growth, Historical Analysis, Mega Trends, Foremost players, Segments and Forecast to 2023 / MRFR. Sep 11, 2019 874
Global Immune Checkpoint Inhibitors Market Report, 2019-2022 - Opdivo & Keytruda Presents Significant Growth Opportunity. Report Sep 5, 2019 826
Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma. Sutaria, Ravi; Patel, Parit; Danve, Abhijeet Sep 1, 2019 1595
Choroidal Melanoma Metastatic to the Contralateral Medial Rectus After Orbital Exenteration. McElnea, Elizabeth; Stevenson, Louis J.; Rosa, Cesar Salinas La; Liew, Sem; Hardy, Thomas G. Sep 1, 2019 3045
Ultrasound-Proven Severe Synovitis Induced by PD-1 Inhibitor Therapy in a Patient Predisposed to Seronegative Inflammatory Arthritis. Kawashiri, Shin-Ya; Iwamoto, Naoki; Ohba, Kojiro; Kawakami, Atsushi Aug 31, 2019 1384
Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma. Sadagopan, Narayanan; Devoe, Craig Aug 31, 2019 1728
A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. Delasos, Lukas; Desai, Aakash; Lia, Nerea Lopetegui; Kethireddy, Nikhila; Ray, Carolyn Aug 31, 2019 3491
Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. Swami, Umang; Monga, Varun; Bossler, Aaron D.; Zakharia, Yousef; Milhem, Mohammed Aug 31, 2019 3740
Gritstone Oncology announces first patient dosed with SLATE. Aug 14, 2019 161
Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. Bari, Shahla; Muzaffar, Jameel; Chan, Austin; Jain, Sanjay R.; Haider, Ahmad M.; Curry, Marjorie Ada Jul 31, 2019 3346
An Atypical Presentation of Lichen Planus-Like Reaction from Pembrolizumab. Lee, Matthew; Seetharamu, Nagashree Jul 31, 2019 3469
Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature. Mobini, Narciss; Dhillon, Rummit; Dickey, Jason; Spoon, Jordan; Sadrolashrafi, Kaviyon Jul 31, 2019 3865
Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer. Agrawal, Kavita; Agrawal, Nirav Jul 31, 2019 2592
Case Series of Recurring Spontaneous Closure of Macular Hole. Elhusseiny, Abdelrahman M.; Flynn, William E. Smiddy Harry W.; Schwartz, Stephen G. Jul 31, 2019 1635
Bristol-Myers Squibb reveals mixed results from Opdivo trial. Jul 26, 2019 197
Bristol-Myers Squibb reveals mixed results from Opdivo trial. Jul 26, 2019 193
Bristol-Myers Squibb's CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival. Jul 26, 2019 580
Bristol-Myers Squibb (NYSE: BMY). Jul 22, 2019 1494
Bristol-Myers Squibb (NYSE: BMY). Jul 16, 2019 1494
Bristol-Myers Squibb (NYSE: BMY). Jul 8, 2019 1494
Bristol-Myers Squibb (NYSE:BMY). Jul 4, 2019 1494
The Three P's: Parotid, PD-L1, and Pembrolizumab. Wiggins, Amanda; Arter, Zhaohui; Kerns, Tamie Jun 30, 2019 1955
Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). Sheng, Iris Y.; Kruse, Megan; Leininger, Kathryn M.; Ornstein, Moshe C. Report Jun 30, 2019 882
Bristol-Myers Squibb (NYSE: BMY). Jun 24, 2019 1494
Jounce Therapeutics initiates Phase 2 EMERGE study of vopratelimab. Jun 18, 2019 234
Bristol-Myers Squibb (NYSE: BMY). Jun 18, 2019 1494
Bristol-Myers Squibb (NYSE: BMY). Jun 13, 2019 1494
New asthma jab and 'gene-silencing' drug approved in Scotland; Healthcare: Five new medicines accepted for use on the NHS. Jun 11, 2019 429
Bristol-Myers Squibb (NYSE:BMY) - Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination in Advanced Hepatocellular Carcinoma at ASCO 2019 -- 3/6/2019. Financial report Jun 4, 2019 507
Bristol-Myers Squibb (NYSE:BMY). Jun 4, 2019 1494
The ADC Market is Fast Evolving: Applications of ADCs are widening and improvements in the manufacturing process meet industry requirements. Johnson, Charlie Jun 1, 2019 1867
The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival. Sunar, Veli; Ates, Ozturk; Aslan, Alma Korcali; Karakas, Yusuf; Altundag, Mustafa Kadri Jun 1, 2019 3961
GOOD NEWS A new approach for the treatment of brain cancer; DR MIRIAM STOPPARD; Helping to keep you fit and healthy. May 31, 2019 107
A new approach for the treatment of brain cancer; DR MIRIAM STOPPARD; Helping to keep you fit and healthy; GOOD NEWS. May 31, 2019 107
Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma. Fazel, Mahdieh; Jedlowski, Patrick M. May 31, 2019 1815
Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. Rogiers, Anne; Boekhout, Annelies; Schwarze, Julia K.; Awada, Gil; Blank, Christian U.; Neyns, Bart May 31, 2019 9923
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naive Vision of a Single Biomarker. Signorelli, Diego; Giannatempo, Patrizia; Grazia, Giulia; Aiello, Marco Maria; Bertolini, Federica; May 31, 2019 11914
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. Zhang, Leyin; Sun, Leitao; Yu, Jieru; Shan, Feiyu; Zhang, Kai; Pang, Xi; Ma, Chenghao; Zhang, Yinan; May 31, 2019 9612
Bristol-Myers Squibb (NYSE: BMY). May 29, 2019 1494
Bristol-Myers Squibb (NYSE:BMY). May 20, 2019 1515
Bristol-Myers Squibb (NYSE:BMY). May 14, 2019 1515
Bristol-Myers Squibb (NYSE: BMY). May 6, 2019 1515
Exelixis starts COSMIC-313 cancer trial. May 3, 2019 215
Exelixis starts COSMIC-313 cancer trial. May 3, 2019 211
Exelixis initiates COSMIC-313 trial. May 1, 2019 163
Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience. Karivedu, Vidhya; Eldessouki, Ihab; Taftaf, Ahmad; Zhu, Zheng; Makramalla, Abouelmagd; Karim, Nagla Clinical report Apr 30, 2019 5527
Bristol-Myers Squibb (NYSE: BMY). Apr 29, 2019 1515
Latest brain tumour trial is Tessa's legacy; DR MIRIAM STOPPARD; Helping to keep you fit and healthy. Apr 22, 2019 423
Dr Miriam Stoppard: Latest brain tumour trial is Tessa Jowell's legacy; Following her death last May, Tessa Jowell's spirit lives on as a new trial given backing thanks to her campaigning is about to kick off. Apr 21, 2019 471
Immunotherapy combination shrinks rare, neuroendocrine cancer: study. Apr 1, 2019 519
Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study. Jung, Maria; Ellinger, Jorg; Gevensleben, Heidrun; Syring, Isabella; Luders, Christine; de Vos, Luka Clinical report Apr 1, 2019 6195
Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Swami, Umang; Swick, Brian; Zakharia, Yousef; Milhem, Mohammed Mar 31, 2019 2238
Espoir dans le traitement du cancer : l'immunotherapie. Mar 29, 2019 777
Gritstone Oncology announces first patient dosed with GRANITE-001. Mar 21, 2019 156
Immuno-oncology: Safety Assessment: Taking the brakes off the immune system with checkpoint inhibitor antibodies. Harper, Kirsty Mar 1, 2019 4365
Nivolumab Induced Seronegative Arthritis in a Patient With Refractory Hodgkin's Lymphoma. Colak, Seda; Omma, Ahmet Mar 1, 2019 1063
PRIMARY MALIGNANT MELANOMA OF THE URINARY BLADDER: CASE REPORT. Kirigin, Monica; Lez, Cvjetko; Sarcevic, Bozena; Soipi, Soip; Jaic, Goran; Ulamec, Monika; Kruslin, Report Mar 1, 2019 1050
Idera Pharmaceuticals completes enrollment in Phase 2 ILLUMINATE-204 trial. Feb 27, 2019 264
Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer. Feb 20, 2019 544
Role of Tumor-infiltrating Lymphocytes in Melanoma. Cihan, Yasemin Benderli Jan 1, 2019 856
Nivolumab + Ipilimumab Shows Efficacy for Untreated Brain Mets; Findings from open-label, phase 2 study in patients with melanoma and untreated brain metastases. Clinical report Aug 22, 2018 252
Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC; And, nivolumab plus ipilimumab linked to better survival in NSCLC with high tumor mutational burden. Apr 16, 2018 314
Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer; One-year overall survival of 61 percent for gemcitabine and cisplatin plus ipilimumab. Apr 11, 2018 267
A Test to Ease the Burden of Selecting Patients for Immunotherapy. Kumar, Vikram S. Apr 1, 2018 1458
Nivolumab Plus Ipilimumab Tops Sunitinib for Advanced Renal CA; Overall survival, objective response higher than sunitinib for untreated clear-cell advanced RCC. Mar 23, 2018 265
A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Yu, Irene S.; Cheung, Winson Y. Report Jan 1, 2018 8936
Immunotherapy in Advanced Gastric Cancer: An Overview of the Emerging Strategies. Magalhaes, Helena; Fontes-Sousa, Mario; Machado, Manuela Jan 1, 2018 5468
Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. Cheng, Xianliang; Zhao, Gang; Zhao, Yunqi Jan 1, 2018 5627
Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma. Shah, Suma; Dunn-Pirio, Anastasie; Luedke, Matthew; Morgenlander, Joel; Skeen, Mark; Eckstein, Chris Jan 1, 2018 1922
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barre Syndrome. Cortellini, Alessio; Parisi, Alessandro; Fargnoli, Maria Concetta; Cannita, Katia; Irelli, Azzurra; Jan 1, 2018 2157
GNQ-209P Mutation in Metastatic Uveal Melanoma and Treatment Outcome. Karim, Nagla Abdel; Eldessouki, Ihab; Taftaf, Ahmad; Ayham, Deeb; Gaber, Ola; Makramalla, Abouelmagd Jan 1, 2018 3014
Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Chaucer, Benjamin; Stone, Abriella; Demanes, Augustus; Seibert, Shawn M. Jan 1, 2018 1500
An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma. Costa, Rubens Barros; Benson, Al; VahidYaghmai; Costa, Ricardo L.B.; Zhou, Haijun; Behdad, Amir; Kap Jan 1, 2018 2917
Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis. Benson, Zachary; Gordon, Sarah; Nicolato, Patricia; Poklepovic, Andrew Jan 1, 2018 2067
Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab. Chokr, Nora; Farooq, Hafsa; Guadalupe, Elizabeth Jan 1, 2018 2929
Bednar Tumour Occurring after Malignant Melanoma Excision. Ferlosio, Amedeo; Prete, Monia Di; Rossi, Piero; Campione, Elena; Orlandi, Augusto Jan 1, 2018 2437
PD-L1 Expression and [CD8.sup.+] T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. Wang, Yangyang; Zhu, Chunchao; Song, Wei; Li, Jun; Zhao, Gang; Cao, Hui Jan 1, 2018 5581
HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response. Wu, Yahong; Zhai, Wenjie; Zhou, Xiuman; Wang, Zhiwei; Lin, Yan; Ran, Ling; Qi, Yuanming; Gao, Yanfen Jan 1, 2018 7782
An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. Chen, Chun-Bing; Abe, Riichiro; Pan, Ren-You; Wang, Chuang-Wei; Hung, Shuen- Iu; Tsai, Yi-Giien; Chu Jan 1, 2018 18729
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. Su, Qiang; Zhang, Xiao-chen; Zhang, Chen-guang; Hou, Yan-li; Yao, Yu-xia; Cao, Bang-wei Jan 1, 2018 5793
Immunotherapies: Exploiting the Immune System for Cancer Treatment. Koury, Jeffrey; Lucero, Mariana; Cato, Caleb; Chang, Lawrence; Geiger, Joseph; Henry, Denise; Hernan Jan 1, 2018 12033
Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Saint-Jean, Melanie; Knol, Anne-Chantal; Volteau, Christelle; Quereux, Gaelle; Peuvrel, Lucie; Broca Jan 1, 2018 6486
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. Vajaitu, Cristina; Draghici, Carmen Cristina; Solomon, Iulia; Lisievici, Cristina Victoria; Popa, Al Jan 1, 2018 7238
The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy. Zhao, Huan; Li, Yuanqi; Wei, Dan; Luo, Hongrong Jan 1, 2018 6860
Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. Pan, Ren-You; Chung, Wen-Hung; Chu, Mu-Tzu; Chen, Shu-Jen; Chen, Hua-Chien; Zheng, Lei; Hung, Shuen- Jan 1, 2018 6452
Immune Checkpoint Inhibitors to Treat Malignant Lymphomas. Witkowska, Magdalena; Smolewski, Piotr Jan 1, 2018 8376
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. Jan 1, 2018 5426
Transforming of the Tumor Microenvironment: Implications for TGF-[beta] Inhibition in the Context of Immune-Checkpoint Therapy. Loffek, Stefanie Jan 1, 2018 6917
Update on the Treatment of Metastatic Urothelial Carcinoma. Bukhari, Nedal; Al-Shamsi, Humaid O.; Azam, Faisal Clinical report Jan 1, 2018 5209
Postmastectomy Radiation Therapy: Are We Ready to Individualize Radiation? Everett, Ashlyn S.; Hunter Boggs, Drexell; De Los Santos, Jennifer F. Report Jan 1, 2018 2965
The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent. Jutzy, Jessica M.S.; Lemons, Jeffrey M.; Luke, Jason J.; Chmura, Steven J. Report Jan 1, 2018 6191
Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. Ruscito, Ilary; Braicu, Elena Ioana; Gasparri, Maria Luisa; Zizzari, Ilaria Grazia Jan 1, 2018 1039
A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab. Poushanchi, Behdod; Vallabh, Hiren; Reynolds, Gorman Joel Jan 1, 2018 1021
Anti-PD-1 Therapy-Associated Perforating Colitis. Celli, Romulo; Kluger, Harriet M.; Zhang, Xuchen Jan 1, 2018 1635
Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. Youssef, Alexey; Kasso, Nawara; Torloni, Antonio Sergio; Stanek, Michael; Dragovich, Tomislav; Gimbe Jan 1, 2018 2098
Antiphospholipid Antibody Induced by Nivolumab. Aburahma, Ahmed; Alhesan, Nour Aljariri; Elounais, Farah; Sitta, Emad Abu Jan 1, 2018 1446
What's new in prostate cancer research? Highlights of GU-ASCO 2014. Kapoor, Anil Report Mar 1, 2014 3451
Malignant skin tumours. Taylor, Michelle Disease/Disorder overview Jan 1, 2014 1286
War on cancer: new success for hyperthermia vs. childhood tumors. Moss, Ralph Oct 1, 2013 3149
Ipilimumab: a first-in-class T-cell potentiator for metastatic melanoma. Chmielowski, Bartosz Report Jan 1, 2013 5548
A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Maki, Robert G.; Jungbluth, Achim A.; Gnjatic, Sacha; Schwartz, Gary K.; D'Adamo, David R.; Keohan, Report Jan 1, 2013 4817
War on cancer: two new drugs emerge for melanoma. Moss, Ralph Oct 1, 2011 2311

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters